29 January 2021
A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC
Selective AXL inhibitors
29 January 2021
A phase II study of the oral selective AXL inhibitor bemcentinib with pembrolizumab in refractory patients with advanced NSCLC
Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.